Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free COIL Stock Alerts

Roquefort Therapeutics (COIL) Competitors

Roquefort Therapeutics logo
GBX 9.30 -0.20 (-2.11%)
As of 06/30/2026 10:27 AM Eastern
Compare

COIL vs. CIR, TILS, VSN, BVXP, and MPH

Should you buy Roquefort Therapeutics stock or one of its competitors? MarketBeat compares Roquefort Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roquefort Therapeutics include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Bioventix (BVXP), and Mereo BioPharma Group plc (MPH.L) (MPH). These companies are all part of the "biotechnology" industry.

How does Roquefort Therapeutics compare to Circassia Group?

Circassia Group (LON:CIR) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Circassia Group has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Circassia Group's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.30%-15.86%

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Circassia Group. Roquefort Therapeutics' average media sentiment score of 0.67 beat Circassia Group's score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Circassia Group Neutral
Roquefort Therapeutics Positive

1.2% of Roquefort Therapeutics shares are held by institutional investors. 36.2% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Circassia Group has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Summary

Circassia Group beats Roquefort Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Tiziana Life Sciences and Tiziana Life Sciences both had 1 articles in the media. Roquefort Therapeutics' average media sentiment score of 0.67 beat Tiziana Life Sciences' score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tiziana Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Roquefort Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tiziana Life Sciences has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Tiziana Life Sciences' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.30%-15.86%

1.2% of Roquefort Therapeutics shares are owned by institutional investors. 36.2% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tiziana Life Sciences has higher earnings, but lower revenue than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Summary

Roquefort Therapeutics beats Tiziana Life Sciences on 5 of the 9 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Verseon?

Roquefort Therapeutics (LON:COIL) and Verseon (LON:VSN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
VerseonN/AN/AN/A-£14.30N/A

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Verseon. Roquefort Therapeutics' average media sentiment score of 0.67 beat Verseon's score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Roquefort Therapeutics Positive
Verseon Neutral

Verseon has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Verseon's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.30% -15.86%
Verseon N/A N/A N/A

1.2% of Roquefort Therapeutics shares are owned by institutional investors. 36.2% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Roquefort Therapeutics beats Verseon on 5 of the 9 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Bioventix?

Bioventix (LON:BVXP) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Bioventix had 1 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 2 mentions for Bioventix and 1 mentions for Roquefort Therapeutics. Bioventix's average media sentiment score of 1.91 beat Roquefort Therapeutics' score of 0.67 indicating that Bioventix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bioventix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Roquefort Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 1.2% of Roquefort Therapeutics shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 36.2% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bioventix has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M6.67£8.12M£140.5211.39
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Bioventix has a net margin of 59.30% compared to Roquefort Therapeutics' net margin of -57,057.07%. Bioventix's return on equity of 65.83% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Roquefort Therapeutics -57,057.07%-18.30%-15.86%

Bioventix has a beta of 0.554, indicating that its share price is 45% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market.

Summary

Bioventix beats Roquefort Therapeutics on 11 of the 12 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Mereo BioPharma Group plc (MPH.L). Roquefort Therapeutics' average media sentiment score of 0.67 beat Mereo BioPharma Group plc (MPH.L)'s score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Roquefort Therapeutics Positive

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.30%-15.86%

1.2% of Roquefort Therapeutics shares are held by institutional investors. 36.2% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Roquefort Therapeutics beats Mereo BioPharma Group plc (MPH.L) on 5 of the 9 factors compared between the two stocks.

Get Roquefort Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for COIL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COIL vs. The Competition

Export
MetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£39.69M£503.01M£7.07B£2.77B
Dividend YieldN/A3.87%2.66%6.14%
P/E Ratio-0.423.1627.24366.58
Price / SalesN/A6,677.46544.4286,243.70
Price / Cash1.4913.1348.5327.87
Price / Book2.4488.3810.957.65
Net Income-£1.52M-£96.07M£3.57B£5.89B
7 Day Performance-8.28%0.94%2.28%-0.10%
1 Month Performance-20.51%-0.20%1.36%-1.75%
1 Year Performance-32.36%74.34%36.72%65.18%

Roquefort Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COIL
Roquefort Therapeutics
N/AGBX 9.30
-2.1%		N/A-34.4%£39.69MN/AN/A9
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
BVXP
Bioventix
N/AGBX 1,655
-3.2%		N/A-38.6%£91.44M£12.54M11.7812

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:COIL) was last updated on 7/1/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel